XBI: SPDR Series Trust SPDR S&P Biotech ETF

XBI Nouvelles

• 13:10 Bernstein raises Regeneron stock price target to $781 on myasthenia gravis data
• 10:30 Mizuho raises Amylyx Pharmaceuticals stock price target to $12 on improved outlook
• 11:33 Mizuho reiterates Outperform rating on Immuneering stock after $25M raise
• 13:24 Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
• 11:50 Opinion: Suze Orman is known for money advice — now she’s sharing her stock picks and biggest investing mistake
• 15:54 Inside XBI: What The SPDR S&P Biotech ETF Offers Investors (NYSEARCA:XBI)
• 07:20 Mega-Cap Crowding Steers Managers To Japan, Europe
• 18:01 Solar, biotech, and health insurance stocks are moving on Friday: here's why
• 12:00 This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine
• 07:10 U.S. Investor Risk Aversion Returns, Expectations Of Losses Deepen In August
• 10:20 Should You Invest in the SPDR S&P Biotech ETF (XBI)?
• 09:30 Retail Investors Boost U.S. Equity Buying, Institutions Slow Stock Selling In July
• 21:45 Erosion Goes On For SPUU (NYSEARCA:SPUU)
• 19:43 Biotech stocks dip as Trump administration mulls patent fee overhaul
• 10:20 4 Calls For Trump’s Pharmaceutical Tariffs
• 06:57 FIAX Has An Attractive Yield, But Still Has To Prove Itself
• 18:19 Trump Threatens Up To 200% Tariffs On Drug Imports. The Market Doesn't Believe Him.
• 17:28 Trump plans tariffs on chips, drugs
• 15:12 Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
• 08:50 2025 Midyear Outlook - Hope Is Not A Strategy
• 19:38 UDOW: Risks And Monthly Leveraged ETFs Report (NYSEARCA:UDOW)
• 03:25 Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT)
• 16:27 Citi initiates coverage on biotech amid improving sentiment in sector
• 00:15 The 1-Minute Market Report June 15, 2025